REGINfo: Biogen Idec Inc - Biotechnologie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

S&P 100 NEWS

> Accenture PLC

> Adobe Systems Inc

> Allstate Corp.

> Altria Group, Inc.

> Amazon.com Inc

> American Express

> American International Group

> Bank of America

> Bank of New York Mellon Corp

> Berkshire Hathaway Inc.

> Biogen Idec Inc

> Booking Holdings

> Bristol-Myers Squibb Co.

> Caterpillar Inc.

> Charter Communication

> Cisco Systems Inc

> Coca Cola Co.

> Colgate-Palmolive

> ConocoPhillips

> Costco Wholesale Corp

> CVS Caremark Corp.

> Eli Lilly & Co.

> Emerson Electric Co.

> Exelon Corporation

> Exxon Mobil Corp.

> Ford Motor Company

> General Dynamics

> General Electric

> General Motors

> Gilead Sciences Inc

> Goldman Sachs Group, Inc.

> Home Depot, Inc

> Honeywell International, Inc.

> International Business Machines (IBM)

> Johnson & Johnson

> JP Morgan Chase & Co

> Kinder Morgan Inc

> Lockheed Martin

> Lowes Companies

> Mastercard Inc A

> McDonald's Corp.

> Medtronic, Inc.

> Merck & Co., Inc.

> Mondelez International Inc

> Morgan Stanley

> NextEra Energy Inc

> Occidental Petroleum

> ...

FEEDS

My Google

Microsoft Live

My Yahoo

COMPANY SEARCH RESULT

$Biogen Idec Inc: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2021.10.17 | 22:20 | Permanent Information Releases / Sales and Revenues

puce Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS - HTML (w)

2021.10.14 | 22:06 | Permanent Information Releases / Sales and Revenues

puce Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting - HTML (w)

2021.10.13 | 12:05 | Permanent Information Releases / General Company News

puce New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience - HTML (w)

2021.10.13 | 12:02 | Permanent Information Releases / General Company News

puce New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis - HTML (w)

2021.09.21 | 14:30 | Permanent Information Releases / General Company News

puce Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience - HTML (w)

2021.09.20 | 13:30 | Permanent Information Releases / General Company News

puce FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) - HTML (w)

2021.09.17 | 15:09 | Permanent Information Releases / General Company News

puce CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis - HTML (w)

2021.09.16 | 13:30 | Permanent Information Releases / Sales and Revenues

puce Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy - HTML (w)

2021.09.15 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam) - HTML (w)

2021.08.02 | 13:30 | Permanent Information Releases / Sales and Revenues

puce Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis - HTML (w)

2021.07.29 | 22:10 | Permanent Information Releases / General Company News

puce Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021 - HTML (w)

2021.07.26 | 22:10 | Permanent Information Releases / General Company News

puce Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021 - HTML (w)

2021.07.23 | 22:30 | Permanent Information Releases / General Company News

puce Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference - HTML (w)

2021.07.22 | 13:05 | Permanent Information Releases / General Company News

puce An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D. - HTML (w)

2021.07.13 | 01:00 | Permanent Information Releases / General Company News

puce Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 169